Changes in Growth Indices and Bone Mineral Density After Infliximab Therapy in Steroid-Naive Pediatric Crohn’s Disease: A Single-Center Retrospective Study
Children · 11.11.2026 · 13 (11) · 1569
DOI: 10.3390/children13111569 ↗Kurz gefasst
Fachartikel in der Zeitschrift Children, online erschienen am 11.11.2026. Verfasst von Naeun Kwak und 6 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: In children, Crohn’s disease (CD) can impair linear growth and skeletal mineralization, resulting in reduced bone mineral density (BMD). We evaluated changes in growth indices and BMD following infliximab (IFX) therapy combined with immunomodulators in pediatric CD.
Methods
This single-center retrospective study included 35 steroid-naive pediatric patients with CD who initiated IFX within 6 months of diagnosis between 2020 and 2025. Changes in inflammatory markers, growth indices, and BMD were assessed from baseline to 1 year after IFX initiation.
Results
After 1 year of IFX therapy, inflammatory markers and clinical disease activity improved significantly. Weight and body mass index z-scores, insulin-like growth factor 1 (IGF-1) z-score, and vitamin D levels increased significantly. Femoral neck BMD z-score increased, although the increase did not remain statistically significant after correction for multiple comparisons. Lumbar spine BMD z-score showed no significant change.
Conclusions
In steroid-naive pediatric patients with CD who started IFX within 6 months of diagnosis, IFX-based therapy was associated with improved inflammatory activity and growth-related parameters. These findings suggest the potential value of such therapy in supporting growth and nutritional recovery, whereas its effects on skeletal health require confirmation in longer-term controlled studies.
Zitieren
APA
Kwak, N., Lee, Y., Lee, S., Jang, K., Choi, S., Choe, B., & Moon, J. (2026). Changes in Growth Indices and Bone Mineral Density After Infliximab Therapy in Steroid-Naive Pediatric Crohn’s Disease: A Single-Center Retrospective Study. Children, 13(11), 1569. https://doi.org/10.3390/children13111569
Vancouver
Kwak N, Lee Y, Lee S, Jang K, Choi S, Choe B, et al. Changes in Growth Indices and Bone Mineral Density After Infliximab Therapy in Steroid-Naive Pediatric Crohn’s Disease: A Single-Center Retrospective Study. Children. 2026;13(11):1569. doi:10.3390/children13111569
BibTeX
@article{Kwak2026,
author = {Kwak, Naeun and Lee, Yoon and Lee, Sangeun and Jang, Kyungmi and Choi, Sujin and Choe, Byung-Ho and Moon, Jung-Eun},
title = {Changes in Growth Indices and Bone Mineral Density After Infliximab Therapy in Steroid-Naive Pediatric Crohn’s Disease: A Single-Center Retrospective Study},
journal = {Children},
year = {2026},
volume = {13},
number = {11},
pages = {1569},
doi = {10.3390/children13111569}
}
EUVIMED